Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
80
SARTF Quote, Financials, Valuation and Earnings
Last price:
$226.33
Seasonality move
:
3.06%
Day range:
$226.33 - $226.33
52-week range:
$165.00 - $226.33
Dividend yield:
0.37%
P/E ratio:
89.69x
P/S ratio:
3.91x
P/B ratio:
4.92x
Volume:
--
Avg. volume:
--
1-year change:
29.67%
Market cap:
$15.6B
Revenue:
$4B
EPS (TTM):
$2.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SARTF
Sartorius AG
|
-- | -- | -- | -- | -- |
|
BNTX
BioNTech SE
|
$201.5M | -$1.97 | -7.26% | -35.17% | $130.51 |
|
IFRX
InflaRx NV
|
$6.4K | -$0.14 | -74.55% | -23.33% | $8.84 |
|
IMTX
Immatics NV
|
$11.7M | -$0.46 | -40.34% | -26.23% | $18.75 |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SARTF
Sartorius AG
|
$226.33 | -- | $15.6B | 89.69x | $0.84 | 0.37% | 3.91x |
|
BNTX
BioNTech SE
|
$91.18 | $130.51 | $23.4B | 191.55x | $0.00 | 0% | 6.64x |
|
IFRX
InflaRx NV
|
$0.91 | $8.84 | $66.6M | -- | $0.00 | 0% | 281.78x |
|
IMTX
Immatics NV
|
$10.35 | $18.75 | $1.4B | 42.21x | $0.00 | 0% | 24.29x |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SARTF
Sartorius AG
|
61.27% | -0.858 | 29.76% | 0.48x |
|
BNTX
BioNTech SE
|
1.37% | 1.157 | 1.31% | 7.36x |
|
IFRX
InflaRx NV
|
2.1% | -3.295 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.13% | 2.015 | 1.3% | 11.05x |
|
MDGEF
Medigene AG
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SARTF
Sartorius AG
|
$461.4M | $182.4M | 2.76% | 5.97% | 16.89% | $198.7M |
|
BNTX
BioNTech SE
|
$668.2M | -$271M | -5.85% | -5.93% | -25.66% | $277M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$50.7M | -38.67% | -40.01% | -220.36% | -$68.9M |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- | -- |
Sartorius AG vs. Competitors
-
Which has Higher Returns SARTF or BNTX?
BioNTech SE has a net margin of 4.74% compared to Sartorius AG's net margin of -33.61%. Sartorius AG's return on equity of 5.97% beat BioNTech SE's return on equity of -5.93%.
Company Gross Margin Earnings Per Share Invested Capital SARTFSartorius AG42.73% $0.51 $9.6B BNTXBioNTech SE63.27% -$1.45 $22.9B -
What do Analysts Say About SARTF or BNTX?
Sartorius AG has a consensus price target of --, signalling downside risk potential of --. On the other hand BioNTech SE has an analysts' consensus of $130.51 which suggests that it could grow by 43.13%. Given that BioNTech SE has higher upside potential than Sartorius AG, analysts believe BioNTech SE is more attractive than Sartorius AG.
Company Buy Ratings Hold Ratings Sell Ratings SARTFSartorius AG0 0 0 BNTXBioNTech SE13 5 0 -
Is SARTF or BNTX More Risky?
Sartorius AG has a beta of 0.933, which suggesting that the stock is 6.74% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.581, suggesting its more volatile than the S&P 500 by 58.073%.
-
Which is a Better Dividend Stock SARTF or BNTX?
Sartorius AG has a quarterly dividend of $0.84 per share corresponding to a yield of 0.37%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius AG pays 32.99% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Sartorius AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SARTF or BNTX?
Sartorius AG quarterly revenues are $1.1B, which are larger than BioNTech SE quarterly revenues of $1.1B. Sartorius AG's net income of $51.2M is higher than BioNTech SE's net income of -$355M. Notably, Sartorius AG's price-to-earnings ratio is 89.69x while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius AG is 3.91x versus 6.64x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SARTFSartorius AG3.91x 89.69x $1.1B $51.2M BNTXBioNTech SE6.64x 191.55x $1.1B -$355M
-
Which has Higher Returns SARTF or IFRX?
InflaRx NV has a net margin of 4.74% compared to Sartorius AG's net margin of -51538.49%. Sartorius AG's return on equity of 5.97% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital SARTFSartorius AG42.73% $0.51 $9.6B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About SARTF or IFRX?
Sartorius AG has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $8.84 which suggests that it could grow by 868.56%. Given that InflaRx NV has higher upside potential than Sartorius AG, analysts believe InflaRx NV is more attractive than Sartorius AG.
Company Buy Ratings Hold Ratings Sell Ratings SARTFSartorius AG0 0 0 IFRXInflaRx NV5 2 0 -
Is SARTF or IFRX More Risky?
Sartorius AG has a beta of 0.933, which suggesting that the stock is 6.74% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.493, suggesting its more volatile than the S&P 500 by 49.333%.
-
Which is a Better Dividend Stock SARTF or IFRX?
Sartorius AG has a quarterly dividend of $0.84 per share corresponding to a yield of 0.37%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius AG pays 32.99% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Sartorius AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SARTF or IFRX?
Sartorius AG quarterly revenues are $1.1B, which are larger than InflaRx NV quarterly revenues of $27.8K. Sartorius AG's net income of $51.2M is higher than InflaRx NV's net income of -$14.3M. Notably, Sartorius AG's price-to-earnings ratio is 89.69x while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius AG is 3.91x versus 281.78x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SARTFSartorius AG3.91x 89.69x $1.1B $51.2M IFRXInflaRx NV281.78x -- $27.8K -$14.3M
-
Which has Higher Returns SARTF or IMTX?
Immatics NV has a net margin of 4.74% compared to Sartorius AG's net margin of -180.65%. Sartorius AG's return on equity of 5.97% beat Immatics NV's return on equity of -40.01%.
Company Gross Margin Earnings Per Share Invested Capital SARTFSartorius AG42.73% $0.51 $9.6B IMTXImmatics NV-- -$0.33 $586.9M -
What do Analysts Say About SARTF or IMTX?
Sartorius AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $18.75 which suggests that it could grow by 81.16%. Given that Immatics NV has higher upside potential than Sartorius AG, analysts believe Immatics NV is more attractive than Sartorius AG.
Company Buy Ratings Hold Ratings Sell Ratings SARTFSartorius AG0 0 0 IMTXImmatics NV9 0 0 -
Is SARTF or IMTX More Risky?
Sartorius AG has a beta of 0.933, which suggesting that the stock is 6.74% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.675%.
-
Which is a Better Dividend Stock SARTF or IMTX?
Sartorius AG has a quarterly dividend of $0.84 per share corresponding to a yield of 0.37%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius AG pays 32.99% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Sartorius AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SARTF or IMTX?
Sartorius AG quarterly revenues are $1.1B, which are larger than Immatics NV quarterly revenues of $23M. Sartorius AG's net income of $51.2M is higher than Immatics NV's net income of -$41.6M. Notably, Sartorius AG's price-to-earnings ratio is 89.69x while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius AG is 3.91x versus 24.29x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SARTFSartorius AG3.91x 89.69x $1.1B $51.2M IMTXImmatics NV24.29x 42.21x $23M -$41.6M
-
Which has Higher Returns SARTF or MDGEF?
Medigene AG has a net margin of 4.74% compared to Sartorius AG's net margin of --. Sartorius AG's return on equity of 5.97% beat Medigene AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SARTFSartorius AG42.73% $0.51 $9.6B MDGEFMedigene AG-- -- -- -
What do Analysts Say About SARTF or MDGEF?
Sartorius AG has a consensus price target of --, signalling downside risk potential of --. On the other hand Medigene AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Sartorius AG has higher upside potential than Medigene AG, analysts believe Sartorius AG is more attractive than Medigene AG.
Company Buy Ratings Hold Ratings Sell Ratings SARTFSartorius AG0 0 0 MDGEFMedigene AG0 0 0 -
Is SARTF or MDGEF More Risky?
Sartorius AG has a beta of 0.933, which suggesting that the stock is 6.74% less volatile than S&P 500. In comparison Medigene AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SARTF or MDGEF?
Sartorius AG has a quarterly dividend of $0.84 per share corresponding to a yield of 0.37%. Medigene AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sartorius AG pays 32.99% of its earnings as a dividend. Medigene AG pays out -- of its earnings as a dividend. Sartorius AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SARTF or MDGEF?
Sartorius AG quarterly revenues are $1.1B, which are larger than Medigene AG quarterly revenues of --. Sartorius AG's net income of $51.2M is higher than Medigene AG's net income of --. Notably, Sartorius AG's price-to-earnings ratio is 89.69x while Medigene AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sartorius AG is 3.91x versus -- for Medigene AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SARTFSartorius AG3.91x 89.69x $1.1B $51.2M MDGEFMedigene AG-- -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 4
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
